ABT Stock Chart & Stats
CHF88.00
-CHF2.00(-2.68%)
At close: 4:00 PM EDT
CHF88.00
-CHF2.00(-2.68%)
Day’s Range― - ―
52-Week RangeCHF63.50 - CHF112.00
Previous CloseN/A
Volume5.00
Average Volume (3M)0.00
Market Cap
CHF154.47B
Enterprise ValueCHF185.82K
Total Cash (Recent Filing)CHF5.60B
Total Debt (Recent Filing)CHF32.61B
Price to Earnings (P/E)35.7
Beta-0.07
Next Earnings
Oct 21, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend Yield2.07%
Share Statistics
EPS (TTM)3.11
Shares Outstanding1,730,383,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.20
Price to Sales (P/S)4.94
P/FCF Ratio29.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF98.89Price Target Upside12.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)4.48
Revenue Forecast (FY)CHF40.82B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring-revenue ModelAbbott’s portfolio spans diagnostics (instrument placements driving recurring reagent/test sales), devices with consumable sensors and disposables, and consumer nutrition. This multi-pillar, repeat-revenue model smooths cash flow and provides durable demand across care settings and cycles.
Strong Free Cash Flow GenerationRobust operating and free cash flow (FCF) generation provides durable financial flexibility: supports R&D, M&A, capex and shareholder returns while absorbing cyclical pressures. Growing FCF also underpins the ability to service higher leverage if operating performance holds.
Pipeline And Regulatory ProgressRecent approvals and submissions expand Abbott’s addressable market: a new blood-based CRC test, CE Mark for Libre Duo and Amulet 360 filing create durable growth channels. Regulatory wins and commercial exclusivity can generate sustained testing volumes and device uptake.
Bears Say
Rising LeverageA meaningful step-up in debt materially increases financial risk and reduces flexibility. Higher leverage raises interest expense sensitivity and limits capacity for opportunistic investment or cushioning against operational shocks if cash flow weakens or rates rise.
Margin Compression And Cooled ReturnsRecent margin decline and lower return on equity indicate structural pressure from mix, cost or pricing dynamics. Sustained margin compression would reduce reinvestment capacity and the conversion of revenue growth into durable earnings and cash generation.
Regulatory & Market-access Timing RiskSeveral high-impact growth opportunities hinge on approvals and reimbursement decisions whose timing is uncertain. Delays or unfavorable coverage decisions would materially slow adoption of new products and compress the expected multi-year revenue trajectory.
Abbott Laboratories News
ABT FAQ
What was Abbott Laboratories’s price range in the past 12 months?
Abbott Laboratories lowest stock price was CHF63.50 and its highest was CHF112.00 in the past 12 months.
What is Abbott Laboratories’s market cap?
Abbott Laboratories’s market cap is CHF154.47B.
When is Abbott Laboratories’s upcoming earnings report date?
Abbott Laboratories’s upcoming earnings report date is Oct 21, 2026 which is in 69 days.
How were Abbott Laboratories’s earnings last quarter?
Abbott Laboratories released its earnings results on Jul 16, 2026. The company reported CHF1.066 earnings per share for the quarter, beating the consensus estimate of CHF1.039 by CHF0.027.
Is Abbott Laboratories overvalued?
According to Wall Street analysts Abbott Laboratories’s price is currently Undervalued.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays a Quarterly dividend of CHF0.509 which represents an annual dividend yield of 2.07%. See more information on Abbott Laboratories dividends here
What is Abbott Laboratories’s EPS estimate?
Abbott Laboratories’s EPS estimate is 1.15.
How many shares outstanding does Abbott Laboratories have?
Abbott Laboratories has 1,730,383,300 shares outstanding.
What happened to Abbott Laboratories’s price movement after its last earnings report?
Abbott Laboratories reported an EPS of CHF1.066 in its last earnings report, beating expectations of CHF1.039. Following the earnings report the stock price went up 9.589%.
Which hedge fund is a major shareholder of Abbott Laboratories?
Currently, no hedge funds are holding shares in CH:ABT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abbott Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF98.89 (12.37% Upside)
CHF98.89 (12.37% Upside)
Blogger Sentiment
Bullish
CH:ABT Sentiment 84%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF140.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.51%
12-Months-Change
Fundamentals
Return on Equity
2.07%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
ABT Company Deck
ABT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.View all CH:ABT earnings summariesABT Net sales Breakdown
12.49% Established Pharmaceutical Products
19.06% Nutritional Products
20.16% Diagnostic Products
48.25% Medical Devices
0.04% Other

ABT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
CHF98.89
▲(12.37% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











